Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports

@article{Mahase2021Covid19PP,
  title={Covid-19: Pfizer’s paxlovid is 89\% effective in patients at risk of serious illness, company reports},
  author={Elisabeth Mahase},
  journal={BMJ},
  year={2021},
  volume={375}
}
In the study, trial participants were randomised 1:1, with half receiving paxlovid and the other half receiving a placebo orally every 12 hours for five days. Of those who were treated within three days of symptom onset, 0.8% (3/389) of patients who received paxlovid were admitted to hospital up to day 28 after randomisation, with no deaths. In comparison, 7% (27/385) of patients who received placebo were admitted, with seven deaths. The statistical significance of these results was reported as… 
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
TLDR
Paxlovid appears to be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.
Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial
TLDR
In this prospective, randomized, placebo-controlled trial, atovaquone did not demonstrate evidence of enhanced SARS-CoV-2 viral clearance compared with placebo, however, based on the observed inverse correlation between atovaqone levels and viral load, additional PK-guided studies may be warranted to examine the antiviral effect of atovaquin in COVID-19 patients.
Phamrmacoligical Therapies for COVID-19: A Comprehensive Review from 2022 Updated Nih, IDSA and ICMR Guidelines
TLDR
This review article gives a comprehensive update on various pharmacological therapies in the light of recently published standard treatment guidelines based on large clinical trials for the treatment of COVID-19.
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand
TLDR
The study reports the promising effectiveness of favipiravir for treating COVID-19 patients and identifies three poor prognostic factors for Day-7 clinical improvement: older age, high baseline NEWS2 score, and low loading dose.
Pandora’s box: Paxlovid, prescribing, pharmacists and pandemic
  • J. Roberts, A. Duncan, K. Cairns
  • Medicine
    Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia
  • 2022
TLDR
Oral antivirals are a potential ‘game changer’ for healthcare provision during the ongoing coronavirus disease 2019 (COVID-19) pandemic and specific considerations exist for the prescribing and dispensing of Paxlovid, a combination of nirmatrelvir and ritonavir.
Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19
TLDR
These findings of the attenuated clinical course of COVID-19 in patients infected with SARS-CoV-2 strains with reduced 3CLpro enzymatic activity greatly endorses the promising result of the aforementioned clinical trial of the3CLpro inhibitor.
Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor
TLDR
Paxlovid is an effective oral treatment for CO VID-19 patients that reduces mortality and can be administered in an outpatient setting, but it cannot substitute COVID-19 immunizations.
Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients
TLDR
It was showed that lithium was able to reduce the number of days of hospital and intensive care unit admission as well as the risk of death, reduces inflammatory cytokine levels by preventing cytokine storms, and also reduced the long COVID syndromes.
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.
TLDR
In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease and the study findings do not support the use of iver mectin for patients with CO VID-19.
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
...
...

References

Covid-19: UK becomes first country to authorise antiviral molnupiravir
The UK’s medicines regulator has issued temporary authorisation of the antiviral drug molnupiravir for the treatment of mild to moderate covid-19 in adults with at least one risk factor for severe